Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
Related Posts
Pope Francis makes first public appearance in five weeks as he leaves hospital
Pope Francis made his first public appearance in more than five weeks on Sunday, waving from a balcony at Rome’s Gemelli hospital before leaving the […]
Ray Dalio says the risk to U.S. Treasuries is even greater than what Moody’s is saying
Moody’s cut the U.S. credit rating one notch to Aa1 from Aaa due to the federal government’s ballooning budget deficit and soaring interest payments.
The ‘weight loss trade’ has stalled. What it will take to revive investor interest
The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.